News Hub | News Direct

All Industries

Article thumbnail News Release

Benchmark International Successfully Facilitated the Transaction Between D.R. Price Engineering & Land Surveying, Inc and Boos Resource & Technology Group

Benchmark International

Benchmark International has successfully facilitated a transaction between Honaker, VA-based D.R. Price Engineering & Land Surveying, Inc. (“D.R. Price”) and Naperville, IL-based Boos Resource & Technology Group (“Boos”). D.R. Price is a multi-discipline engineering and surveying firm that provides a broad spectrum of structural engineering, civil engineering, mining engineering, land planning, land surveying, and construction surveying services. “D.R. Price President Richard Bostic grew a fantastic niche business serving the coal mining and other industries in Southwest Virginia and its environs,” commented Benchmark Senior Transaction Director William Sullivan. “The company adds a key piece to the Boos regional growth strategy and will contribute greatly to the acquirer’s capabilities and reach in the region. This transaction was a great fit from both an integration and a cultural standpoint, and we are proud to have supported our client throughout this process to a successful conclusion.” Founded in 1988, D.R. Price serves residential, commercial, and government customers throughout Virginia, West Virginia, and Kentucky. The company uses the latest industry technologies to perform its services, including GPS surveying, drone technology, electronic data collection, and AutoCAD mapping. D.R. Price has grown significantly in recent years, largely due to increasing customer referrals, a steady flow of new customers, and expanded project scopes. Boos Resource and Technology Group is an environmental and energy-focused solutions provider that delivers timely and cost-effective construction management, infrastructure, natural gas, and industrial services to clients across the United States and beyond. Europe: Michael Lawrie at +44 (0) 161 359 4400 / Americas: Sam Smoot at +1 (813) 898 2350 / Africa: Anthony McCardle at +27 21 300 2055 / ABOUT BENCHMARK INTERNATIONAL: Benchmark International is a global M&A firm that provides business owners with creative, value-maximizing solutions for growing and exiting their businesses. Benchmark International has handled over $11 billion in transaction value across various industries from offices across the world. With decades of M&A experience, Benchmark International’s transaction teams have assisted business owners with achieving their objectives and ensuring the continued growth of their businesses. The firm has also been named the Investment Banking Firm of the Year by The M&A Advisor and the Global M&A Network as well as the #1 Sell-side Exclusive Privately-held M&A Advisor in the World by Pitchbook and Refinitiv's Global League Tables. Contact Details Brittney Zoeller +1 813-898-2350 Company Website

July 22, 2024 06:00 AM Eastern Daylight Time

Article thumbnail News Release

The Financial Select Sector SPDR Fund (XLF): A Gateway to Financial Institutions

Select Sector SPDR

The Financial Select Sector SPDR Fund (XLF) offers investors a path to engage with the U.S. financial sector. Comprised of the S&P 500's financial stocks, XLF offers a diversified approach to investment in this dynamic segment of the economy. A Balanced Investment Opportunity XLF's strategy involves a modified market capitalization-weighted index, focusing on some of the most significant U.S. financial companies. This method aims to provide a balanced mix of stability from large-cap entities and potential growth opportunities across various financial sub-sectors including banking, credit services, capital markets, and insurance. Insight into XLF's Holdings* The fund's holdings are components of the S&P 500 and offer investors a comprehensive view of the financial landscape, featuring: Berkshire Hathaway B (12.94%): A conglomerate with diverse interests JP Morgan Chase (10.21%): A global financial services firm Visa A (7.26%): A leader in digital payments Mastercard A (6.36%): Renowned for payment processing solutions Bank of America Corp (4.75%): A multinational banking and financial services institution Wells Fargo (3.64%): Offering a wide range of financial services Goldman Sachs (2.56%): Specializes in investment banking and management S&P Global (2.51%): Known for its financial data and analytics American Express Co (2.31%): Providing payment card services globally Progressive Corp (2.14%): Recognized for its insurance products and services An Accessible Path to the Financial Sector The Financial Select Sector SPDR Fund ( XLF ) is designed to be an accessible option for those interested in the financial sector. It allows investors to potentially benefit from the sector’s dynamics without needing to select individual stocks. The fund's broad diversification and focus on significant financial institutions aim to offer a balanced exposure to the sector's potential. For More Information To learn more about how the Financial Select Sector SPDR Fund (XLF) operates and whether it fits into your investment strategy, we invite you to visit our website or reach out to our investor relations team. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. *Holdings, Weightings & Assets as of 6/30/24 subject to change DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: Website: *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007679 EXP 9/30/24 Contact Details Dan Dolan +1 203-935-8103 Company Website

July 22, 2024 05:00 AM Eastern Daylight Time

Article thumbnail News Release

OpenBet Scores Big with Euro 2024: Over 140 Million Bets Processed

AM Europe

OpenBet successfully processed over 140 million bets during the UEFA Euro 2024 tournament, demonstrating the scalability and reliability of its technology. The company facilitated a peak of £850 million wagered in a single month, highlighting the significant interest in the competition. England and Spain were the most popular bets throughout the knockout stages, reflecting the strong support for these traditional powerhouses. Additionally, Austria experienced a surge in bets following their surprising victory, showcasing the dynamic nature of the betting landscape. Overall, OpenBet's performance during Euro 2024 underscores its position as a leading provider of sports betting solutions. The company's ability to handle high volumes of bets while maintaining a secure and reliable experience for customers is a testament to its commitment to innovation and excellence. Contact Details Kimberly C. Addis +44 7766 676396

July 22, 2024 04:02 AM Eastern Daylight Time

Article thumbnail News Release

BDA Announces 2025 Bermuda Risk Summit Dates

Bermuda Business Development Agency

Hamilton, Bermuda, July 19 th 2024: The Bermuda Risk Summit is set to take place from March 10-12, 2025, at the Hamilton Princess & Beach Club. This premier event promises to bring together industry leaders and experts for three days of insightful discussions and networking opportunities. Kendaree Burgess, COO of the Bermuda Business Development Agency, remarked, " The 2025 Bermuda Risk Summit is a must attend event for Bermuda’s Risk sector, bringing together industry thought leadership, innovation and interest from those seeking to make Bermuda their domicile of choice. This event highlights Bermuda's leadership in risk management and offers a unique platform for industry experts to network and collaborate.” The 2024 Bermuda Risk Summit saw over 450 attendees, with 40% traveling from 30 different countries. The summit featured 50 industry-leading speakers, addressing crucial topics that shape the risk management landscape. Sponsorship Opportunities Sponsorship opportunities for the Bermuda Risk Summit 2025 are now available! Sponsors will have the chance to gain significant visibility and connect with influential leaders in the risk management sector. If you are interested in sponsorship, click here or email Early Bird Registration and Accommodation Members of the public are encouraged to register early. An early bird rate of $395 will be available until September 30. To avoid disappointment, click here to reserve your hotel room online or call 1-441-295-3000, or the Global Reservations Centre at 1-800-441-1414, using the booking code: ‘Bermuda Risk Summit’ to take advantage of our preferred rate. For more information, please visit our website or contact us at BERMUDA BUSINESS DEVELOPMENT AGENCY BDA.BM +1 441 292 0632 CONNECTING BUSINESS The BDA encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. The Bermuda Business Development Agency (BDA) encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Contact Details Bermuda’s Business Development Agency (BDA) Melvin Dickinson +1 441-707-0038 Company Website

July 19, 2024 01:56 PM Eastern Daylight Time

Article thumbnail News Release

Tonix Pharmaceuticals Awarded potential 34 million dollar Contract with U.S. Department of Defence

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to share exciting news about a significant achievement for the company. Tonix Pharmaceuticals has been awarded a potential contract worth up to $34 million over five years by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense. This contract aims to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections, thereby enhancing the medical readiness of military personnel in biological threat environments. Dr. Lederman explained that Tonix’s program will concentrate on the optimization and development of its TNX-4200 program. The goal is to develop an orally available CD45 antagonist with broad-spectrum efficacy against various viral families through extensive preclinical evaluation. The program is expected to establish essential physicochemical properties, pharmacokinetics, and safety attributes to support an Investigational New Drug (IND) submission, ultimately funding a first-in-human Phase 1 clinical study. The agreement with DTRA is a strategic move to address the DoD’s objective of protecting U.S. Joint Forces from potential biological weapon threats. The DoD announced in December 2022 that it aims to move beyond the traditional ‘one bug, one drug’ approach and is seeking broad-spectrum drugs, as predicting which viruses or how many may be deployed in a biological threat scenario is challenging. Dr. Lederman emphasized that the collaboration with DTRA underscores Tonix Pharmaceuticals' commitment to advancing medical readiness and protection for military personnel. By developing a broad-spectrum antiviral agent, Tonix aims to provide a versatile and robust solution to potential viral threats, enhancing the preparedness and resilience of the U.S. military in diverse and unpredictable biological threat environments. The TNX-4200 program’s focus on creating an effective, orally available antiviral agent highlights Tonix’s innovative approach to addressing complex medical challenges. The successful development of this broad-spectrum antiviral could significantly impact the way viral infections are managed in military and potentially civilian populations, offering a proactive measure against a wide array of viral threats. Tonix Pharmaceuticals continues to be at the forefront of medical innovation, dedicated to developing cutting-edge solutions that meet the evolving needs of the healthcare and defense sectors. The support from the DoD through this substantial contract is a testament to the potential and importance of Tonix’s TNX-4200 program in safeguarding the health and readiness of military personnel against biological threats. Contact Details Proactive Investors +1 604-688-8158

July 19, 2024 12:48 PM Eastern Daylight Time

Article thumbnail News Release

Mainz BioMed Seeks FDA Breakthrough Device Designation for Advanced Colorectal Cancer Test

Mainz Biomed N.V.

Mainz BioMed CEO Guido Baechler joined Steve Darling from Proactive to announce the company has submitted an application to the U.S. Food and Drug Administration requesting Breakthrough Device Designation for its innovative non-invasive Next Generation colorectal cancer screening product. This product incorporates a novel portfolio of mRNA biomarkers. Achieving this designation could potentially expedite the approval process, significantly benefiting early cancer detection efforts. Baechler emphasized that the regulatory submission is backed by consistently strong results from the company's clinical studies, ColoFuture and eAArly Detect, as well as data from a comprehensive pooled study encompassing both the European and U.S. cohorts, which were presented at ASCO 2024. These studies have culminated in the final configuration of the Next Generation Test. This test integrates the Fecal Immunochemical Test with proprietary mRNA biomarkers and is enhanced by an advanced AI and machine learning algorithm. This integrated approach is set to be employed in the FDA premarket approval study. The Next Generation Test configuration was rigorously evaluated in a clinical setting involving 295 subjects from 21 specialized gastroenterology centers across the United States. The results underscored the exceptional efficacy of Mainz Biomed’s multimodal screening test, which allows for precise differentiation among colorectal cancer, advanced adenomas, non-advanced adenomas, and samples with no pathological findings. The FDA’s Breakthrough Devices Designation program is designed to accelerate the development, assessment, and review of medical devices and combination products that provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions. This designation for Mainz BioMed's colorectal cancer test could pave the way for quicker market access and wider availability of this critical diagnostic tool. Contact Details Proactive North America +1 604-688-8158

July 19, 2024 12:38 PM Eastern Daylight Time

Article thumbnail News Release

Immersive Engagement Is The Future – CEO Speaks About Company's Innovations That Keep Pushing What's Possible


By Johnny Rice, Benzinga Ann Hand, CEO of Super League Enterprise Inc (NASDAQ: SLE), was recently interviewed by Benzinga. Super League helps brands reach Gen Z and Gen Alpha in the 3D environments that they frequent. Platforms like Roblox (NYSE: RBLX), Fortnight and others represent significant opportunities to marketers as they allow for very interactive and immersive experiences. Ms. Hand spoke about the exciting developments her company has been making, such as SOUNDZ, its latest tool for driving real engagement and commerce. Learn more here: Featured photo by Vinicius "amnx" Amano on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 Company Website

July 19, 2024 09:00 AM Eastern Daylight Time

Video Image
Article thumbnail News Release

Old Slip Capital Announces New Miami Office, Issues Advisory for ERISA by James Lukezic, Managing Director

Rev Up Marketers

Old Slip Capital has announced the opening of its new office in Miami, FL. The company has also issued an important advisory to plan sponsors, pointing to the advantages of trusting ERISA Fiduciary Advisors. Old Slip Capital's new office in Miami will further add a growth potential to its prospects. It has also shared insights for Plan Sponsors to help them derive the best from ERISA. The advisory focuses on explaining the difference between an ERISA Fiduciary Advisor and a Standard Broker or Advisor, and helps in understanding that selecting a Standard Broker or Advisor is simply not good enough. According to James Lukezic, Managing Director at Old Slip Capital, there are some obvious dangers of not hiring an ERISA Fiduciary Advisor under section 3(38) or 3(21) or both: "Plan Sponsors think that simply having an Advisor at the table is enough until they (Plan Sponsor) realize that a Standard or Retail Advisor is giving them arm’s length advice and not truly taking on liability or responsibility for that advice. With a sanctioned ERISA Fiduciary Advisor, Plan Sponsors can shift that liability to the ERISA Advisor and his or her firm; that includes personal liability on the part of the investment committee members". The advisory goes on to point out that plaintiffs’ class action lawyers in fiduciary breach lawsuits, the Department of Labor in ERISA plan audits, courts, and insurers have focused increased attention on how well ERISA plan fiduciaries follow procedural due process. Actions (or inactions) of committees and individual investment committee fiduciaries are scrutinized and judged in increasing detail, causing fiduciaries to wonder if they are up to date on all of the best practices for plan governance. According to Old Slip Capital, understanding the roles of Fiduciaries and the types of Fiduciaries generally causes confusion. There are Trust Fiduciaries, Administrative Fiduciaries and ERISA Fiduciaries; the latter being the most important. The role of the ERISA Fiduciary is critical, as this advisor is the glue that holds the Retirement Plan together, his or her advice to the Investment Committee steers the success of the plan in a big way. The advisory further explains that competence to act as a fiduciary on the investment committee means more than just having subject matter expertise. It also means having the time needed to devote to the fiduciary role. Putting aside the potential conflicts of interest that a director would face in switching hats from corporate director to plan fiduciary, even a director with the requisite expertise to act as a fiduciary, typically lacks the time (and probably the inclination) to perform more than an oversight role. Furthermore, the Board of Directors should never be left in the position of acting as the Investment Committee. Unfortunately, this is precisely the form of fiduciary governance structure that is in place with the overwhelming majority of employer sponsored plans. Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements. Contact Details Old Slip Capital Partners James Lukezic Company Website

July 19, 2024 08:41 AM Eastern Daylight Time

Article thumbnail News Release

The Rising Importance Of Minor Cannabinoids In The Growing Edible Market


By Kyle Anthony, Benzinga With society’s growing acceptance of cannabis consumption, a segment that has risen in popularity is edibles, which are simply products containing cannabinoids that one can eat or drink. While edibles containing cannabinoid compounds, such as THC (tetrahydrocannabinol), which induces a euphoric feeling, or CBD (cannabidiol), which has therapeutic attributes, are familiar to many, edibles containing minor cannabinoids are gaining traction among consumers due to the compound’s unique properties and potential health benefits. As such, the minor cannabinoid-infused edibles market stands at the precipice of potentially remarkable growth, fueled by discernible shifts in consumer behavior. The 2023 Minor Cannabinoid Market Recently, BayMedica, a firm focused on producing and commercializing rare cannabinoids and a subsidiary of InMed Pharmaceuticals (NASDAQ: INM), released a report detailing the growth of the minor cannabinoid market in 2023. The report utilized data from Headset, the largest dataset in the cannabis industry. It focuses on the growth, competition and consumer habits associated with minor cannabinoid-infused edibles in ten regulated cannabis states, which represent 85 million of the 158 million people living in areas where recreational cannabis is legal. The edible market experienced a robust 5.4% revenue surge in 2023, totaling $2.097 billion for the year. This growth was driven partly by innovative developments with minor cannabinoids. Gummies, a subset of the edible product category, exhibited strong sales, while minor cannabinoid-infused edibles witnessed an impressive 47% year-over-year growth, with sales totaling $391 million for the year. While there was a slight decline (i.e., from $14.29 to $12.54) in the average edible item price, the increased demand by consumers, strong growth prospects of the category and reduced input production costs were factors that appealed to cannabinoid brands seeking to gain strategic positioning in the industry. Minor Cannabinoids Explained Minor cannabinoids are naturally occurring compounds found in cannabis plants, distinct from the more well-known cannabinoids like THC and CBD. While THC and CBD dominate in terms of quantity and research focus, minor cannabinoids are changing the cannabinoid landscape due to their holistic capabilities. Minor cannabinoids are found in much smaller quantities than their more abundant counterparts THC and CBD, and are relatively rare in the full spectrum of cannabinoids that are present in a fully mature cannabis plant. Some notable minor cannabinoids include: Cannabichromene (CBC): CBC is recognized as a "booster" for other cannabinoids and is known for its interaction with the body's natural endocannabinoid, anandamide (also known as the bliss molecule). CBC seems to prevent the reabsorption of anandamide, enabling this bliss molecule to remain in the bloodstream for a longer duration. Tetrahydrocannabivarin (THCV): THCV is non-psychoactive and has a chemical structure similar to THC but produces different effects. It may act as an appetite suppressant, making it of interest for weight loss and for reducing unwanted food cravings that are typical with adult-use cannabis products. Additionally, As a CB1 receptor neutral antagonist, it can stimulate focus and energy, opening it up to a wide range of potential applications as an ingredient in both topical and ingestible products. Cannabidivarin (CBDV): CBDV is similar to CBD in its lack of psychoactive effects. Possible use cases for this minor cannabinoid span from the promotion of brain health and immune health to gut health. Cannabinol (CBN): CBN is formed as THC degrades and is mildly psychoactive. It is known for its potential sedative effects, which could be useful for treating insomnia. Additionally, CBN may have antibacterial properties and could aid in pain relief​. All cannabinoids work with the endocannabinoid system (ECS), which was only discovered in the late 1980’s. Every human being has an endocannabinoid system, and every cell type in the body has cannabinoid receptors that work as lock and key, with the over 140 cannabinoids that are known to exist. The ECS regulates and controls many of the body’s most critical functions, and it has been hypothesized that ECS activity may have therapeutic potential in almost all diseases affecting humans. Some of the more powerful cannabinoids, sometimes known as minor or rare cannabinoids, are impractical to extract either because they are represented in such small quantities in the plant or because their separation from other cannabinoids is cost-prohibitive. However, advancements in biosynthesis and synthetic chemistry, such as those utilized by companies like BayMedica, LLC, enable the production of these cannabinoids at commercial scales, paving the way for new therapeutic applications​. Minor Cannabinoids Gaining Momentum In 2023, 24 of the top 50 selling edibles incorporated minor cannabinoids, reflecting a significant shift in market trends. The innovation underpinning this material adoption speaks to the commitment of leading edible brands that are identifying formulations that resonate with a growing and diverse consumer base. This strategic action helped brands counter price compression by establishing a premium price and propelled the growth of minor-infused edible revenue. As detailed in the report, brands incorporating minor cannabinoids in cannabis products strategically command a premium, boasting a 6.3% higher average item price than products with standard THC formulations. This pricing trend reflects market recognition and a willingness to pay more for products enriched with minor cannabinoids, providing an opportunity for differentiation in a crowded market. It also gives credence to the entourage effect, a theory that various cannabis compounds work together to create specific effects and benefits. Using this theory, combining minor cannabinoids with major cannabinoids like THC and CBD allows for more medicinal benefits upon consumption, like pain relief. Cannabis brands incorporating minor cannabinoids also enjoy a remarkable 73% higher average EQ (Equivalent) price compared to THC-only counterparts. The use of EQ pricing is essential for fair product comparison, considering factors like potency or weight and highlighting consumers' tangible willingness to pay more for the inclusion of minor cannabinoids. Finally, given the diverse nature of minor cannabinoids, the products have high customer value and appeal. Tapping into their therapeutic properties empowers consumers to experience various health and wellness benefits, fostering a healthier and more balanced lifestyle. Commercial Adoption Commercialization of minor cannabinoids via edibles has provided insight into which minors are resonating with consumers. As illustrated in the report, CBN has established and maintained sales leadership within the minor cannabinoid landscape. Given its potential sedative effects, it can be hypothesized that consumer demand is being driven by individuals using it as a sleep aid. While CBG continues to exhibit strong year-over-year sales, market analysts project a potential deceleration in the future. Projections suggest that CBG, once the minor cannabinoid leader, may make way for emerging cannabinoids to take the forefront. In contrast to prior years, both CBC and THCV exhibited strong sales in 2023. For CBC, as research on its potential benefits as a mood enhancer gains momentum, its popularity in consumer preferences is likely to fuel sustained growth in sales, positioning it as a key player in the evolving cannabis market. THCV witnessed a substantial 140% year-over-year growth. Its improved affordability due to production enhancement made by lead processors like BayMedica has made THCV more accessible in the edibles market. Furthermore, rising awareness of its physical energy and appetite-suppressing effects, especially when combined with THC variants, positions it as a key player in shaping the evolving landscape of cannabinoid-based products. The Path Forward The edibles market is witnessing a paradigm shift as consumers are redefining their priorities around cannabis consumption, moving away from smoking in favor of the targeted therapeutic effects and consistent experiences offered by edibles. This move means the cannabis product landscape will be transformed in the coming years; as such, edible brands will need to align with the evolving needs of consumers, steering the industry towards a future where minor cannabinoids in edibles take center stage in the pursuit of holistic well-being. As a stakeholder in this industry transformation, BayMedica continues to focus on scaling its operations and expanding its product offerings to meet the growing demand for high-quality cannabinoids in various applications that may be used by a growing customer base. Featured photo by Elsa Olofsson on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 Company Website

July 19, 2024 08:30 AM Eastern Daylight Time

12345 ... 3599